Literature DB >> 32720650

Essential Thrombocythemia Presenting with Recurrent Priapism: A Case Report and Review of Literature.

Shailendra Prasad Verma1, Nidhish Kumar1, Mili Jain2, Anil K Tripathi1.   

Abstract

BACKGROUND Priapism is rarely reported as a complication in patients with essential thrombocythemia at presentation. We could find very few such cases of essential thrombocythemia while searching the literature. A combined modality of treatment is used in the form of chemotherapy and procedures like repeated aspiration and instillation of phenylephrine to treat essential thrombocythemia presenting with recurrent priapism. CASE REPORT A 31-year-old man presented to the Urology Department with priapism for the last 24 h. He had previously had multiple similar episodes in the last 20 days and 1 episode of prolonged penile erection 5 months ago. On examination, his penis was erect, swollen, and painful. There was no organomegaly. The priapism was managed with repeated aspiration and instillation of phenylephrine. Routine investigations showed marked thrombocytosis. Subsequent investigations done in the Clinical Hematology Department revealed increased megakaryocytes in bone marrow and presence of JAK2V617F mutation. After confirmation of diagnosis, cytoreductive therapy (hydroxyurea 500 mg twice a day) and acetyl salicylic acid 75 mg once a day was initiated. With this treatment, the platelet count normalized over a period of 2 months and no further episodes of priapism were noted; however, the patient developed erectile dysfunction. CONCLUSIONS Essential thrombocythemia can present with priapism as the first manifestation. Early suspicion, diagnosis, and management is needed to prevent erectile dysfunction. Erectile dysfunction is usually irreversible after long-standing priapism.

Entities:  

Year:  2020        PMID: 32720650      PMCID: PMC7414838          DOI: 10.12659/AJCR.924455

Source DB:  PubMed          Journal:  Am J Case Rep        ISSN: 1941-5923


Background

Priapism is an unwanted prolonged penile erection without any sexual arousal. It has been reported in patients with various non-malignant and malignant hematological disorders, including myeloproliferative neoplasms. Chronic myeloid leukemia (CML) is the most common myeloproliferative neoplasm (MPN) associated with priapism [1-3]. It is rarely reported as a complication in patients with essential thrombocythemia. We could find only a few cases in the recent literature [4-7]. A combined modality treatment is being used in the form of chemotherapy and procedures like repeated aspiration and instillation of phenylephrine to treat essential thrombocytosis presenting with recurrent priapism [8,9].

Case Report

A previously healthy 31-year-old man was admitted to the Urology Department with a history of penile erection that began the previous day. His penis was erect, swollen, and painful. There was no history of any drug intake, sexual activity, masturbation, use of alcohol, or any illicit drug use. The patient gave a history of many similar previous episodes lasting for many hours with spontaneous recovery in the last 20 days. He also had a history of one such episode 5 months ago that was relieved by conservative management. He was referred to the Clinical Hematology Outpatient Department for evaluation of abnormal blood test results. The general examination was otherwise unremarkable; there were no pallor, lymphadenopathy, or hepatosplenomegaly. Laboratory investigations showed hemoglobin 13 gm/dl, total leucocyte count 18.3×109/L, and platelet count 1424×109/L. A peripheral blood smear examination revealed thrombocytosis with giant platelets (Figure 1). Bone marrow aspirate and biopsy showed increased numbers of megakaryocytes, with giant and bizarre megakaryocytes present in nests (Figure 2). JAK2V617F mutation was detected and BCR-ABL by RT-PCR was negative. Serum biochemical test results were unremarkable.
Figure 1.

Peripheral blood smear (Leishman stained 400×): large platelet clumps. One myelocyte and basophil is also seen in the background.

Figure 2.

Bone marrow aspirate (Leishman stained 400×): Hypercellular marrow with megakaryocyte cluster. Inset: Hyperlobated megakaryocyte.

This patient was managed conservatively by repeated aspiration of corpora cavernosa and instillation of phenylephrine in the Urology Department. With repeated aspiration and instillation of phenylephrine, the penis become flaccid. After the confirmation of diagnosis, the patient received hydroxyurea 500 mg twice a day, and acetyl salicylic acid 75 mg once a day was added when platelet count decreased below 1000×109/L. Subsequent to treatment with hydroxyurea and acetyl salicylic acid, no episode of priapism was noted. His platelet count decreased to below 400×109/L at the end of 2 months. As a consequence of prolonged priapism, he developed erectile dysfunction (ED), which did not improve, even at 6-month follow-up.

Discussion

Priapism is a sustained penile erection in the absence of sexual activity. It is generally defined as an unwanted erection lasting more than 4 h [10]. It can be high-flow or low-flow. High-flow priapism is due to increased blood influx into the cavernous bodies, usually due to an arteriocavernosal fistula. It is also called nonischemic, as cavernous blood gases are neither hypoxic nor acidotic. Low-flow priapism has a veno-occlusive origin and is known as ischemic priapism because diminished blood efflux from the cavernous bodies causes hypoxic and acidotic cavernous blood gases [6]. Ninety percent of men with ischemic priapism lasting more than 24 h develop erec-tile dysfunction. Ischemia persisting for more than 24–48 h causes endothelial damage and trabecular destruction leading to irreversible fibrosis and calcification, resulting in ED [11]. Priapism is a urological emergency. Hematological conditions may be associated with major episodes of priapism, as well as stuttering priapism (recurrent temporary episodes of priapism). Well-documented hematological conditions causing priapism are hemolytic disorders (e.g., homozygous sickle cell disease); myeloproliferative neoplasms (e.g., chronic myeloid leukemia [CML] and polycythemia vera [PV]); acute leukemia (e.g., acute myeloblastic leukemia [AML] and acute lymphoblastic leukemia [ALL] with high counts); plasma cell disorders (e.g., myeloma and amyloidosis); and hypercoagulable states. Sickle cell disease is the most common hematological disorder, while CML is the most common leukemia associated with priapism [3,12]. The pathophysiology of priapism in hematological conditions includes hyperleukocytosis leading to aggregates of leukemia cells in the corpora cavernosa in CML and acute leukemias, clogging by RBCs in sickle cell disease, and stasis of platelets in essential thrombocytosis leading to low-flow (ischemic) priapism [4,8,12]. According to a 2016 WHO report, essential thrombocytosis (ET) is a chronic myeloproliferative neoplasm (MPN) that primarily involves the megakaryocytic lineage. It is characterized by sustained thrombocytosis ≥450×109/L in peripheral blood, increased numbers of large mature megakaryocytes in bone marrow, exclusion of CML, PV, and MDS, and presence of JAK-2, CALR, or MPL mutation. Other causes of thrombocytosis must be excluded, including other MPNs [13]. Clinically, ET is characterized by episodes of thrombosis and/or hemorrhage. In ET, priapism is a very rare complication and only a few cases are found in the literature. Table 1 shows the review of similar cases reported in the literature.
Table 1.

Review of similar cases reported in the literature.

AuthorsAge (years)ComplaintsCo-morbidityTreatmentOutcome
Matsumoto Y et al. 2019 [4]71Painful erection for 3 daysETAspiration of corpus cavernosum and injection of phenylephrine and oral hydroxyureaErectile dysfunction
Goel S et al. 2017 [5]21Painful erection for 5 daysETRepeated aspiration and installation of phenylephrineAt 6 months asymptomatic, no further priapism, did not mention about ED
Durosinmi MA et al. 1990 [6]45Painful erectionETBilateral cavernostomyErectile dysfunction
Kudo K et al. 2000 [7]12Painful erectionETMedical managementRecovered, no erectile dysfunction
When priapism is associated with a hematological condition, adult guidelines recommend systemic treatment of the underlying disorder along with intra-cavernous treatment to minimize the duration of erection and the risk of consequent long-term ED [14,15]. Conservative approaches like apheresis and chemotherapy (e.g., steroids, hydroxyurea, and imatinib) can manage many patients, especially children [14]. Aspiration of corpora cavernosa and instillation of phenyl ephrin can be tried in adults with severe and prolonged symptoms for rapid response and flaccidity of the penis. If these procedures also do not work, surgical correction (e.g., cavernosa-corpus spongiosum shunt) can be tried [1,16,17].

Conclusions

Clinicians should consider essential thrombocythemia in patients presenting with recurrent priapism. It should be suspected early and investigated promptly. General measures, cytoreduction, and evacuation of the corpora cavernosa should be done early to avoid erectile dysfunction. Once the etiological diagnosis is confirmed, specific therapies targeting the underlying neoplasm can be started.
  16 in total

1.  Priapism

Authors:  Pierre Bondil; Damien Carnicelli
Journal:  Rev Prat       Date:  2017-06

2.  American Urological Association guideline on the management of priapism.

Authors:  Drogo K Montague; Jonathan Jarow; Gregory A Broderick; Roger R Dmochowski; Jeremy P W Heaton; Tom F Lue; Ajay Nehra; Ira D Sharlip
Journal:  J Urol       Date:  2003-10       Impact factor: 7.450

3.  Essential thrombocythaemia associated with priapism: a case report.

Authors:  M A Durosinmi; O A Badejo; B A Ayoade; C O Odelana
Journal:  East Afr Med J       Date:  1990-08

4.  Priapism as a rare presentation of chronic myeloid leukemia.

Authors:  Pradeep Kumar; Khaliqur Rahman; Surabhi Kumari; Manish Kumar Singh; Ruchi Gupta; Soniya Nityanand
Journal:  J Cancer Res Ther       Date:  2018 Oct-Dec       Impact factor: 1.805

5.  How I treat priapism.

Authors:  Uzoma A Anele; Brian V Le; Linda M S Resar; Arthur L Burnett
Journal:  Blood       Date:  2015-03-25       Impact factor: 22.113

Review 6.  [Clinical features of essential thrombocythemia in three children].

Authors:  K Kudo; K Horibe; K Iwase; M Kondo; S Kojima
Journal:  Rinsho Ketsueki       Date:  2000-11

Review 7.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

8.  Conservative management of priapism secondary to leukemia.

Authors:  Marco Castagnetti; Laura Sainati; Fiorina Giona; Stefania Varotto; Modesto Carli; Waifro Rigamonti
Journal:  Pediatr Blood Cancer       Date:  2008-09       Impact factor: 3.167

9.  Trends in Sickle Cell Disease-related Priapism in U.S. Children's Hospitals.

Authors:  Hsin-Hsiao Scott Wang; Katherine W Herbst; Jennifer A Rothman; Nirmish R Shah; John S Wiener; Jonathan C Routh
Journal:  Urology       Date:  2015-12-07       Impact factor: 2.649

10.  Priapism secondary to chronic myeloid leukemia treated by a surgical cavernosa-corpus spongiosum shunt: Case report.

Authors:  Min Qu; Xin Lu; Lei Wang; Zhiyong Liu; Yinghao Sun; Xu Gao
Journal:  Asian J Urol       Date:  2018-12-15
View more
  2 in total

1.  Essential thrombocythemia with (type2) calreticulin presented as stuttering priapism case report and review of literature.

Authors:  Elrazi Awadelkarim Ali; Abdulqadir Jeprel Nashwan; Mohamed A Yassin
Journal:  Clin Case Rep       Date:  2020-11-18

2.  Stuttering priapism in a pediatric patient with pheochromocytoma-induced thrombocytosis.

Authors:  Sarayuth Boonchai; Surasak Sangkhathat; Wison Laochareonsuk; Worapat Attawettayanon
Journal:  Urol Ann       Date:  2022-07-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.